The QUELL-CV trial is a randomized, double-blind study designed to establish optimal dosing for future Phase 3 development. BGE-102 distinguishes itself through its ability to penetrate the brain and engage a unique binding site, a profile that yielded significant hsCRP reductions during Phase 1 testing. BioAge Labs and its partner, HitGen, expect to release topline data from this proof-of-concept trial in the second half of 2026.
HitGen CEO Dr. Jin Li noted that the transition to Phase 2 confirms the efficacy of their drug-discovery platform in addressing complex biological targets. Kristen Fortney, CEO of BioAge, added that the collaboration remains focused on leveraging these novel chemical starting points to expand their pipeline. HitGen, which has supported over 600 global partners since its founding, continues to provide the foundational technology behind the compound's development.
Comments (0)
No comments yet. Be the first!